| Authors | Gainche, L. Berlowitz, D. J. LeGuen, M. Ruehland, W. R. O'Donoghue, F. J. Trinder, J. Graco, M. Schembri, R. Eckert, D. J. Rochford, P. D. Jordan, A. S. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Journal of Clinical Sleep Medicine |
| PubMed ID | 27568894 |
| Year of Publication | 2016 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/27568894 |
| DOI | /10.5664/jcsm.6044 |
| Abstract | STUDY OBJECTIVE: Obstructive sleep apnea (OSA) is common in individuals with tetraplegia and associated with adverse health outcomes. The causes of the high prevalence of OSA in this population are unknown, but it is important to understand as standard treatments are poorly tolerated in tetraplegia. Nasal congestion is common in tetraplegia, possibly because of unopposed parasympathetic activity. Further, nasal obstruction can induce OSA in healthy individuals. We therefore aimed to compare nasal resistance before and after topical administration of a sympathomimetic between 10 individuals with tetraplegia (T) and 9 able-bodied (AB) controls matched for OSA severity, gender, and age. METHODS: Nasal, pharyngeal, and total upper airway resistance were calculated before and every 2 minutes following delivery of approximately 0.05 mL of 0.5% atomized phenylephrine to the nostrils and pharyngeal airway. The surface tension of the upper airway lining liquid was also assessed. RESULTS: At baseline, individuals with tetraplegia had elevated nasal resistance (T = 7.0+/-1.9, AB = 3.0+/-0.6 cm H2O/L/s), that rapidly fell after phenylephrine (T = 2.3+/-0.4, p = 0.03 at 2 min) whereas the able-bodied did not change (AB = 2.5+/-0.5 cm H2O/L/s, p = 0.06 at 2 min). Pharyngeal resistance was non-significantly higher in individuals with tetraplegia than controls at baseline (T = 2.6+/-0.9, AB = 1.2+/-0.4 cm H2O/L/s) and was not altered by phenylephrine in either group. The surface tension of the upper airway lining liquid did not differ between groups (T = 64.3+/-1.0, AB = 62.7+/-0.6 mN/m). CONCLUSION: These data suggest that the unopposed parasympathetic activity in tetraplegia increases nasal resistance, potentially contributing to the high occurrence of OSA in this population. |
http://www.ibas.org.au/what-we-do/publications/3872842
Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....
Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...
RESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE
The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...
Kudos to Dr. Lauren Booker & Dr. Jen Cori on their JOEM publication examining fatigue detection alarms in rural truck drivers. Their study explores the alarms' effectiveness, accuracy, and habituation, offering key insights into fatigue management.
HONORING EXCELLENCE IN RESEARCH
Congratulations to Prof. Anne Holland and A/Prof. Narelle Cox for being featured in the NHMRC's 10 of the Best - 16th Edition. Their work exemplifies groundbreaking research delivering extraordinary outcomes.
WORLD SLEEP DAY ON 14TH MARCH 2025
The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 14th March 2025.
Grants Success: The Institute for Breathing and Sleep (IBAS) has received two research grants from the Austin Medical Research Foundation (AMRF) for 2025. Congratulations to Dr Charissa Zaga and Dr Catherine Hill from IBAS.
© 2025 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
